Cash burn, lack of profitability stalled Zymergen plans ahead of Ginkgo merger deal - San Francisco Business Times

  • 📰 SFBusinessTimes
  • ⏱ Reading Time:
  • 52 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 24%
  • Publisher: 68%

Business News News

Business Business Latest News,Business Business Headlines

The filings come in advance of a merger with a rival for $300 million — a small fraction of the billions Zymergen once hoped to generate.

Ginkgo does not make products for itself but uses genetic engineering to make bacteria for its customers to use in industrial processes.

On Dec. 15, Zymerge’s board looked at various strategic initiatives, including a potential carve-out of the company’s automation business, either with a financing and separation or as a sale. By the end of the month, Zymergen’s board considered three options: sell the company, carve out the automation business, possibly in combination with other Zymergen businesses, or continue to operate as a standalone company through a private investment in public equity, or PIPE, transaction or an at-the-market, or ATM, equity offering.

It was those same costs, and the ballooning size of Zymergen's workforce, that co-founders of the now-nine-year-old company believed was necessary to meet what they forecast to be unparalleled demand for environmentally friendly, biological solutions that would supersede the use of fossil fuels in many products.

With a PIPE offering, the company approached 10 financial parties, but all of them cited Zymergen’s cash burn as one of the reasons not to participate.

 

Thank you for your comment. Your comment will be published after being reviewed.
Please try again later.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

 /  🏆 78. in BUSİNESS

Business Business Latest News, Business Business Headlines